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Estimates of overdiagnosis in mammography screening range from 1% to 54%. This review explains such
variations using gradual implementation of mammography screening in the Netherlands as an example. Breast
cancer incidence without screening was predicted with a micro-simulation model. Observed breast cancer
incidence (including ductal carcinoma in situ and invasive breast cancer) was modeled and compared with pre-
dicted incidence without screening during various phases of screening program implementation. Overdiagnosis
was calculated as the difference between the modeled number of breast cancers with and the predicted number of
breast cancers without screening. Estimating overdiagnosis annually between 1990 and 2006 illustrated the
importance of the time at which overdiagnosis is measured. Overdiagnosis was also calculated using several
estimators identiﬁed from the literature. The estimated overdiagnosis rate peaked during the implementation phase
of screening, at 11.4% of all predicted cancers in women aged 0–100 years in the absence of screening. At steady-
state screening, in 2006, this estimate had decreased to 2.8%. When different estimators were used, the over-
diagnosis rate in 2006 ranged from 3.6% (screening age or older) to 9.7% (screening age only). The authors
concluded that the estimated overdiagnosis rate in 2006 could vary by a factor of 3.5 when different denominators
were used. Calculations based on earlier screening program phases may overestimate overdiagnosis bya factor 4.
Sufﬁcient follow-up and agreement regarding the chosen estimator are needed to obtain reliable estimates.
breast neoplasms; early detection of cancer; incidence; mammography; mass screening; overdiagnosis; risk
Abbreviation: DCIS, ductal carcinoma in situ.
INTRODUCTION
Mammography screening has been shown to be effective
in reducing breast cancer mortality (1–4), but the magnitude
of the harms of screening is less well established. One of the
harms of screening is overdiagnosis: detection of breast
cancers that would not have become symptomatic during a
woman’s lifetime if no screening had taken place.
Screening is expected to increase the observed incidence
of breast cancer among women in the targeted age group,
partly because of overdiagnosis but also because of the ad-
vanced diagnosis of breast cancer. At prevalence screening,
mammography may detect breast cancers from a pool of
preclinical tumors that exist in a population, which increases
the observed incidence. At subsequent screens, future in-
cidence trends—breast cancer incidence in industrialized
countries increases by calendar time (4)—are brought for-
ward in time, which may also lead to an excess of breast
cancers compared with a situation without screening.
Theoretically, those tumors for which the diagnosis is
advanced by screening will not be diagnosed when they
would have been if no screening had taken place. The period
during which the diagnosis is advanced is called ‘‘lead
time.’’ When the lead time has elapsed, the incidence among
previously screened women is expected to fall to a level be-
low that predicted without screening (‘‘deﬁcit incidence’’).
The deﬁcitin incidence in the previously screened agegroup
is expected to balance out the excess in incidence in the
screening ages. In practice, this is not entirely the case (5–
7) and is referred to as overdiagnosis.
The frequency at which overdiagnosis occurs is a topic
of strong debate. In a meta-analysis of overdiagnosis in
randomized breast cancer screening trials and various
population-based screening programs, Biesheuvel et al. (8)
111 Epidemiol Rev 2011;33:111–121found that estimates ranged between  4% and 54% of all
expected cancers (including invasive breast cancers only).
More recent analyses estimated the rate of overdiagnosis to
be 52%–54% of all expected cancers without screening in
women of the screening age, meaning that 1 of 3 cancers in
a screened population is overdiagnosed (5, 9). Modeling
studies, on the contrary, estimated overdiagnosis to be be-
tween 1% of all diagnosed breast cancers in a screened
population (6) and 3% of all predicted breast cancers in
the total population (10).
The question thus arises regarding why overdiagnosis
estimates differ to such an extent between those studies.
In this analysis, we discuss differences between key studies
of overdiagnosis. Using the gradual implementation of na-
tionwide breast cancer screening of more than 1 million
Dutch women as an example, we focus on the importance
of the time at which overdiagnosis is measured. To enable
a comparison between various estimates of overdiagnosis,
we calculate rates using several different denominators.
MATERIALS AND METHODS
MIcro-simulation SCreening ANalysis model (MISCAN)
Biennial mammography screening in the Netherlands
started in 1990 and was gradually implemented in the
whole country between 1990 and 1997 (‘‘implementation
phase’’), targeting women in the age group 49–69 years.
Between 1998 and 2001, the screening program was ex-
tended to women aged 49–74 years (‘‘extension phase’’).
A ‘‘steady-state phase’’ of screening was reached in 2002,
when the number of ﬁrst screening examinations and sub-
sequent examinations with an interval of more than 30
months from the previous screening remained stable. Annu-
ally, more than 1 million women are invited to participate in
the program; 82% of the invited population attends
screening.
The implementation, extension, and steady-state phases of
the Dutch screening program were modeled in MISCAN (11,
12), designed to assess the effects of screening on a popula-
tion. The model consisted of 2 parts: a part in which 1) the
individual life histories of women in a nonscreened popula-
tion were simulated, and 2) a part in which a screening pro-
gram was modeled and the inﬂuence of mammography
screening onthese lifehistories was determined. We modeled
the Dutchfemale populationaged0–100 years in 1989. Inthe
model, some of these women may develop preclinical inva-
sive breastcancerduringtheir lives,whichmayormaynot be
preceded by screen-detectable ductal carcinoma in situ
(DCIS). In the absence of screening, preclinical screen-de-
tectable DCIS may progress to invasive cancer, become clin-
ically diagnosed, or regress. Preclinical invasive tumors may
grow into a successively larger preclinical stage of disease, as
a Markov-like stage transition process. They also may be-
come symptomatic and consequently diagnosed. If screening
takes place, preclinical lesions can also become screen de-
tected, depending on their size and the sensitivity of the test.
The rates at which these transitions occur, the mean
duration of preclinical DCIS and invasive cancer, and the
sensitivity of screening mammography were estimated by
using data from the Comprehensive Cancer Centers (13) and
screening organizations in the Netherlands (14). These data
included the observed age-speciﬁc incidence in the Nether-
lands between 1990 and 2006; the age-speciﬁc and stage-
speciﬁc incidenceofclinicallydiagnosedandscreen-detected
cancer; the age-, stage-, and screening-round–speciﬁc cancer
detection rates; and interval cancer rates since the start of
screening. By minimizing the deviance between observed
and modeled breast cancer incidence, screen detection, and
interval cancer rates, the optimal model parameters were
chosen. A chi-square test was used to test goodness of ﬁt.
With the model, the observed incidence in the Netherlands
and various other countries could be reproduced reasonably
(15–17). We assumed that no mammography screening
took place outside the organized program because screen-
ing participation is high, especially among women who
have previously attended (82% in the target population,
95% of previous attendees) (14). Furthermore, a survey of
women older than the screening age showed no evidence for
opportunistic screening (18).
Model parameters
In the best-ﬁtting model, we estimated the duration of
preclinical DCIS to be Weibull distributed, with a mean of
2.6 years at all ages. The duration of preclinical invasive
cancer has an exponential distribution with a mean esti-
mated to increase by age, from 1.0 year at age 20 to 3.9
years from age 65 onward. The sensitivity of mammography
was 72% for DCIS, 47% for stage T1a, 62% for stage T1b,
90% for stage T1c, and 95% for stage T2þ, and it was
assumed not to change over time. We further estimated that
18% of all tumors had a screen-detectable DCIS stage, of
which 11% progressed to invasive breast cancer, 5% was
clinically diagnosed, and 2% regressed.
Overdiagnosis calculations
To calculate the rate of overdiagnosis in the Netherlands,
wemodeledbreastcancerincidenceinthepresenceofscreen-
ing. The model that ﬁtted best to the observations was
then compared with predicted breast cancer incidence in
the absence of screening. With this approach, screened and
nonscreenedpopulationswereexactlythesame,withasimilar
background risk of developing breast cancer. Both DCIS and
invasive cancer were included in the overdiagnosis estimate,
because, in the model, overdiagnosis can occur when
1. preclinical DCIS, detected by screening, would have re-
gressed if no screening had taken place (Figure 1A);
2. preclinical DCIS, detected by screening, would not have
progressed to invasive cancer during a woman’s lifetime
if no screening had taken place (Figure 1B);
3. preclinical DCIS, detected by screening, would have pro-
gressed to invasive cancer but would not have become
symptomatic during a woman’s lifetime if no screening
had taken place (Figure 1C); and
4. preclinical invasive breast cancer, detected by screening,
would not have become symptomatic during a woman’s
lifetime if no screening had taken place (Figure 1D).
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T0, age 0–100 years. E represents the number of excess breast
cancers in women of screening age, calculated as the differ-
ence in the modeled number of breast cancers with and the
predicted number of cancers without screening. D is the
number of deﬁcit breast cancers in the age groups exceeding
the screening limit, calculated as the difference in the pre-
dicted number of breast cancers without and the modeled
number of cancers with screening. T0, age 0–100 years repre-
sents the total number of breast cancers predicted in a pop-
ulation aged 0–100 years without screening.
To illustrate the extent to which overdiagnosis estimates
are inﬂuenced by the denominator used, various estimators
are applied to the modeled and predicted breast cancer
incidence in the Netherlands. We searched the PubMed litera-
ture to identify alternative estimators to calculate overdiagno-
sis. With the query ‘‘(‘breast neoplasms’[MeSH Terms] OR
(‘breast’[All Fields] AND ‘cancer’[All Fields]) OR ‘breast
cancer’[All Fields]) AND (‘overdiagnosis’[All Fields] OR
‘over-diagnosis’[All Fields] OR ‘overdetection’[All Fields]
OR ‘over-detection’[All Fields]),’’ a total of 158 titles were
obtained. Only primary research or review articles in English
that gave explicit estimates of overdiagnosis in breast cancer
screening trials and population-based mammography screen-
ing were considered relevant. Using these criteria, we in-
cluded a total of 15 papers. On the basis of the literature
references in these articles, 1 other paper was also included.
Data on the denominator used to deﬁne the population at risk,
the time period of screening, and the length of follow-up after
screening ended were extracted from each study. An overview
of the 16 studies obtained, with their estimates of overdiag-
nosis,is presented in Table 1. Thestudiesweregroupedbythe
estimator used to calculate overdiagnosis:
1. (E   D)/T0, age 0–100 years, which is the relative increase in
breast cancers due to overdiagnosis (E   D) compared
with the predicted number of breast cancers in the female
population aged 0–100 years in a situation without
screening. This estimator was used by de Koning et al.
(10), who estimated the overdiagnosis rate to be 3%.
2. (E   D)/T0, screening age and older, which is the relative
increase in breast cancers due to overdiagnosis (E   D)
compared with the predicted number of breast cancers
in women of the screening age and older in a situation
without screening. Three previous studies used this esti-
mator, with overdiagnosis estimates ranging between 1%
and 30.5% (7, 19, 20).
3. (E   D)/T0, screening age, which is the relative increase in
breast cancers due to overdiagnosis compared with the
predicted number of breast cancers in women of the
screening age in a situation without screening. This
method was used in 3 studies (5, 21–23), with overdiag-
nosis estimates varying between 4.6% and 52%.
4. (E   D)/T1, screening age, which is the fraction of over-
diagnosed cancers of all diagnosed breast cancers in
women of the screening age in a situation with screening.
The 3 studies that used this estimator assessed overdiag-
nosis to be 1%–12% (6, 24, 25).
5. (E   D)/SD, which is the fraction of all screen-detected
(SD) cancers that is overdiagnosed. Welch and Black
(26) recalculated the results of the Swedish Malmo ¨ trial
(7) with this denominator and estimated the overdiagno-
sis rate to be 24%.
Figure 1. Stages at which overdiagnosis can occur: A) When preclinical ductal carcinoma in situ (DCIS), detected by screening, would have
regressed if no screening had taken place; B) when preclinical DCIS, detected by screening, would not have progressed to invasive cancer during
a woman’slifetime if no screening had takenplace; C) when preclinical DCIS, detectedby screening,would have progressed to invasivecancer but
would not have become symptomatic during a woman’s lifetime if no screening had taken place; and D) when preclinical invasive breast cancer,
detected by screening, would not have become symptomatic during a woman’s lifetime if no screening had taken place. Dot-ﬁlled boxes; stage at
which a breast canceris screen detected;grey-shaded boxes: stagesof the naturalhistory of thetumor avertedby screendetection; crosses:death
from causes other than breast cancer.
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breast cancer for women of the screening age in a situa-
tion with screening compared with the predicted number
of breast cancers in women of the same age in a situation
without screening. The estimator can be corrected for
lead time, for instance, by shifting the predicted inci-
dence without screening forward in time. Three studies
used this method (9, 27, 28); their overdiagnosis esti-
mates ranged between  4% and 54%.
7. T1, screening age/(T1, screening age, corrected), which is the rel-
ativerisk of breastcancer for women of the screeningage
in a situation with screening compared with the predicted
number of tumors in a situation with screening if no
overdiagnosis would take place (T1, screening age, corrected).
This method was used by Martinez-Alonso et al. (29),
who estimated the overdiagnosis rate to range between
0.4% and 46.6%.
Overdiagnosis was calculated by applying estimators 1–6 to
the modeled and predicted numbers of breast cancers with
and without screening in the Netherlands. Doing so demon-
strates the impact of using different denominators on the
estimated overdiagnosis rate. The overdiagnosis rate using
estimator 6 (T1, screening age/T0, screening age) was calculated
without a correction for lead time. A lead-time correc-
tion—for instance, by shifting the expected incidence with-
out screening 2.5 years forward in age (comparable to the
studies by Morrell et al. (9) and Jonsson et al. (28)—should
result in an estimate in between those of estimators 3 and 6.
Estimator 7 was not used, because it is not possible in MIS-
CAN to model the incidence of breast cancer without as-
suming some degree of overdiagnosis. The outcomes were
compared with the overdiagnosis rate obtained by using
estimator 1 (E   D)/T0, age 0–100 years.
To illustrate the importance of the time at which over-
diagnosis is estimated, the rate was calculated for each
year between 1990 and 2006, during the implementation,
extension, and steady-state phases of the screening program.
Only in a steady state will the estimators provide an un-
biased estimate of overdiagnosis.
RESULTS
From the moment that screening started in the Nether-
lands, observed breast cancer incidence among women of
the screening ages increased (Figure 2 A–J). Related to the
growing number of women screened and the relatively high
Table 1. Estimators for Overdiagnosis and Follow-up Time to Correct for Lead Time, as Reported in the Literature
Estimator Method Used: First Author,
Year (Reference No.)
Follow-up Allowed to
Correct for Lead Time
Overdiagnosis
Estimate
1. (E   D)/
T0, age 0–100 years
de Koning, 2006 (10) Modeled follow-up during remaining lifetime, in the
steady-state phase of the screening program
3%
2. (E   D)/
T0, screening age
and older
Moss, 2005 (19) 5–13 years of follow-up after randomization  5.8% to 30.5%
Zackrisson, 2006 (7) 15 years of follow-up after the trial ended 10%
Puliti, 2009 (20) 5–10 years of follow-up past the screening age 1% to 13%
3. (E   D)/
T0, screening age
Paci, 2006 (21) Modeled follow-up during remaining lifetime, in the
ﬁrst 5 years of the screening program
4.6%
Jorgensen, 2009
(4 countries) (5)
Follow-up of 7–9 years after full implementation of
screening or 10–11 years after the program started
52%
Jorgensen, 2009
(Denmark) (5)
Follow-up of 2–10 years after full implementation of
the program
33%
4. (E   D)/
T1, screening age
Duffy, 2005 (6) Modeled follow-up during remaining lifetime, at the
end of the screening trial
1% to 2%
Olsen, 2006 (24) Modeled follow-up during remaining lifetime, in the
ﬁrst 2 screening rounds
4.8%
Duffy, 2010 (Sweden) (25) Modeled follow-up during remaining lifetime, at the
end of the screening trial
12%
5. (E   D)/SD Welch, 2010 (26) 15 years of follow-up after the trial ended 24%
6. T1, screening age/
T0, screening age
Zahl, 2004 (27) 1–4 years of follow-up after full implementation of
the screening program
45% to 54%
(excluding DCIS)
Jonsson, 2005 (28) 7–15 years of follow-up since screening started  4% to 54%
(excluding DCIS)
Morrell, 2010 (9) 4–6 years of follow-up after full implementation of
the program
30% to 42%
(excluding DCIS)
7. T1, screening age/
T1, screening age, corr
Martinez-Alonso, 2010 (29) Modeled follow-up during remaining lifetime, since
screening started
0.4% to 46.6%
Abbreviations: D, number of deﬁcit breast cancers in the age groups exceeding the screening limit, calculated as the difference in the number of
breast cancerswithout and withscreening;DCIS, ductal carcinoma in situ; E, numberof excessbreast cancersin the screeningages,calculatedas
the difference in the number of breast cancers with and without screening; SD, number of screen-detected cancers; T0, predicted number of breast
cancers in the absence of screening; T1, modeled total number of breast cancers in the presence of screening; T1, corr, total number of breast
cancers in the presence of screening minus the number of overdiagnosed cancers.
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phase of the program, the difference between the observed
incidence rate of women of the screening ages and the pre-
dicted incidence in the absence of screening (‘‘excess in-
cidence’’) increased. At the end of the implementation
phase (1996–1997), the invitation rate in the population
no longer increased and excess incidence remained stable.
Because part of the women aged 50–54 years reached the
lower age limit for screening and had a prevalence screen-
ing, their incidence was higher than that of women aged
55–59 years, of whom the majority was invited for a sub-
sequent screening round at this time.
In 1998, the upper age limit for the screening program
was extended to women aged 70–74 years. At the peak of
this extension phase, in 1999, the number of invited women
and screening examinations with an interval of more than
2.5 years from the previous screening examination rose
strongly, resulting in a higher detection rate. Consequently,
excess breast cancer incidence among women of the screen-
ing ages also increased sharply (Figure 2F). The excess
dropped again when all women aged 70–74 years had been
reinvited to screening at least once (in 2002, Figure 2H)
and a ‘‘steady-state’’ phase of the screening program was
reached. From 2002 onward, the excess incidence among
women of the screening ages remained fairly constant.
In the age groups that passed the screening age ( 70
years between 1990 and 1997,  75 years from 1998 on-
ward), the observed breast cancer incidence dropped to
a level lower than the predicted incidence without screening
(Figure 2). Because of lead time, generally estimated to be
between 2 and 4 years (20, 30), the drop in incidence among
women no longer screened is predicted to occur 2–4 years
later than the increase in the screening ages, when all tumors
would have been clinically diagnosed if no screening had
taken place. Indeed, from 1994 onward, a deﬁcit in breast
cancer incidence was observed. From the moment that the
majority of women were invited for a subsequent screening,
in 1996, the deﬁcit reached its maximum. The deﬁcit in the
incidence rate almost disappeared in the year the screening
program was extended to include women aged 70–74 years.
This extension phase lasted until 2001; the deﬁcit in inci-
dence among women aged 75 years or older was expected to
be observed between 2003 and 2005. Indeed, the deﬁcit in-
creased during these years.
Our overdiagnosis estimates were based on the modeled
incidence of breast cancer and the predicted incidence with-
out screening. Overall, the model reproduced the observed
incidence reasonably well. Between 1990 and 1993, how-
ever, the simulated incidence among women of the screen-
ing ages (50–69 years) was higher than observed, whereas,
between 2001 and 2006, the modeled incidence was lower.
When the modeled breast cancer incidence in a screening
situation was compared with the predicted incidence with-
out screening, the estimated overdiagnosis rate in the total
population during the implementation phase of screening
increased from 1.0% of all predicted breast cancers in
1990 to 11.4% in 1993 (Table 2). In 1993, the modeled
excess in breast cancers peaked (17.1% of all predicted
cancers in women aged 50–69 years), while the modeled
deﬁcit in incidence among women no longer screened was
0.8% of all predicted cancers in that agegroup. The estimate
of overdiagnosis decreased the morewomen had subsequent
screens, to 5.6% in 1997.
During the extension phase, the overdiagnosis estimate
increased to 10.0% in 1999, after which it decreased to
4.7% in 2001. During the steady-state phase of screening,
the estimate ﬁrst increased to 4.9% in 2003 but then dropped
to 2.8% of all predicted breast cancers in 2006. In 2006, the
excess of breast cancers in the age group was 7.0%; the
deﬁcit was 11.7% (Table 2). Most of the deﬁcit was ex-
pected directly when screening ceased: in the age group
70–74 years before 1998 and in the age group 75–79 years
from 1998 onward. In 2006, a small deﬁcit was also pre-
dicted among women aged 80–84 years.
Depending on the denominator used to deﬁne the popu-
lation at risk, the overdiagnosis estimate at steady-state
screening may increase to 8.9% if the rate is calculated as
a fraction of all screen-detected cancers (Table 3, estimator
5, 2006). This rate is 3.2 times higher than the estimate that
uses all predicted breast cancers in women aged 0–100 years
in the denominator (Table 3, estimator 1, 2006) but has the
same numerator. If calculated as a fraction of all diagnosed
tumors among women of the screening age in a screening
situation (Table 3, estimator 4, 2006), the estimate would be
4.6%. The estimated rates of overdiagnosis calculated as
a relative increase among women of the screening age and
older (Table 3, estimator 2, 2006) or women of the screening
age only (Table 3, estimator 3, 2006) were 3.6% and 5.0%,
respectively. Without an adjustment for lead time, the over-
diagnosis rate calculated for women of the screening age only
would be 9.7%: 3.5 times higher than the baseline estimate
(Table 3, estimator 6, 2006). Overdiagnosis also depended on
the year it was measured. Calculations based on years in
which a screening program was not yet fully implemented
were 4 times higher than estimates based on steady screening
(Table 3, estimator 1, 1993 vs. 2006). The estimated over-
diagnosis rate by year of measurement and by estimator is
s h o w ni nT a b l e3 .
DISCUSSION
The estimated overdiagnosis rate peaked during the im-
plementation phase of screening at 11.4% of all predicted
cancers in women aged 0–100 years in the absence of
screening. Five years after implementation was completed,
in 2006, this estimate had decreased to 2.8%. If different
estimators were used, the overdiagnosis rate in 2006 would
range between 3.6% (screening age and older) and 9.7%
(screening age only). The estimate of overdiagnosis is thus
strongly dependent on the time it was calculated and the
denominator used to deﬁne the population at risk.
Our ﬁndings seem to strongly differ from those in some
recent publications, with estimated overdiagnosis rates up to
approximately 50% (5, 8, 9, 27). This paper may perhaps
not resolve the controversy, but it does explain why reported
epidemiologic estimates may differ to such an extent. Using
gradual implementation of nationwide breast cancer screen-
ing of more than 1 million Dutch women, we illustrated that
a steady-state screening situation and sufﬁcient follow-up to
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Epidemiol Rev 2011;33:111–121Figure 2. Observed and modeled breast cancer incidence per 100,000 woman-years in the presence and absence of screening between 1990 and
2006 (values after years indicate percentage of the target population aged 49–69 years invited, fraction of prevalent screenings). A) 1990: 9.2%, 74%;
B) 1992: 47.4%, 77%; C) 1994:74.3%, 49%;D) 1996: 92.0%, 39%; E)1998: 80.8%, 20%; F)1999:91.8%, 19%; G) 2000:94.4%, 18%; H) 2002: 96.1%,
14%; I) 2004: 95.8%, 14%; J) 2006: 92.2%, 13%. Solid lines, modeled with screening; dashed lines, modeled without screening; triangles, observed.
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cancer incidence and to calculating overdiagnosis correctly.
In several studies, the ﬁrst years of the screening program
were included in the overdiagnosis estimate (21, 23, 29). A
relatively large proportion of women will have a prevalence
screen in these years, which will increase the number of
excess breast cancers. In the worst-case scenario, this could
have resulted in overestimation of the overdiagnosis rate by
a factor of 4(Table 3, estimator 1, 1993 vs. 2006). Of course,
ﬁrst (prevalent) screening rounds of women who reach the
lower age limit for screening should be included in an over-
diagnosis estimate. However,the proportionofwomenreach-
ing this age will be stable only during steady-state screening.
Several studies based their analyses on the period after
implementation of screening but still may not have fully
accounted for lead time (5, 9, 22, 27) because they calculated
overdiagnosis by using average breast cancer incidence
during this phase. However, even during the steady-state
phase, overdiagnosis may further drop by a factor of 1.7
(Table 3, estimator 1, 2003 vs. 2006) as the number of
women contributing to the deﬁcit in incidence still in-
creases. A compensatory drop in incidence will reach its
maximum only if all women in the age group past the
screening age had been invited to screening when they were
eligible. Moreover, some tumors may have a lead time lon-
ger than 5 years. On the basis of the estimated distribution of
the lead time of breast cancer in our study (the best-ﬁtting
model assumed a Weibull-distributed lead time with a me-
dian of 2 years and a mean lead time of 3.7 years), approx-
imately 20% of all tumors will have a lead time of more than
5 years, and 5% will have a lead time of more than 10 years.
Ideally, the lead time of these tumors should be accounted
for by calculating overdiagnosis several years after screen-
ing has reached the steady-state phase.
Overdiagnosis estimates will be affected by the denomi-
nator used to deﬁne the population at risk. Various estima-
tors were used in this study, resulting in overdiagnosis
estimates differing by a factor of 3.5. By calculating over-
diagnosis for women of all ages, we also included women
who will never be screened and will not be at risk of over-
diagnosis. If overdiagnosis is calculated as a relative risk for
women of the screening ages only (5, 21, 22), overdiagnosis
could be 1.8 times higher than if women of all ages are
included (Table 3, estimator 3 vs. estimator 1, 2006). How-
ever, the impact of a screening program is sometimes ob-
served at a later age; by limiting the denominator to the
screened age group, the lifetime effect of screening is not
given justice. Alternatively, the risk of overdiagnosis can
Table 2. Predicted Excess and Deﬁcit in Breast Cancers and Overdiagnosis in the Netherlands
a
Phase and Years
T0, age
0–69/74
years
T1, age
0–69/74
years
Eage
0–69/74
years,%
T0, age
69/74–100
years
T1, age
69/74–100
years
Dage
69/74–100
years,%
Eage 0–69/74
years – Dage
69/74–100 years
(E 2 D)/
T0, age 0–100
years,%
Implementation phase
1990–1991 15,237 15,481 1.6 7,207 7,197 0.1 234 1.0
1991–1992 15,646 17,065 9.1 7,201 7,184 0.2 1,402 6.1
1992–1993 15,606 17,719 13.5 7,240 7,214 0.4 2,087 9.1
1993–1994 15,695 18,381 17.1 7,458 7,400 0.8 2,628 11.4
1994–1995 16,039 18,490 15.3 7,499 7,405 1.3 2,357 10.0
1995–1996 16,149 18,550 14.9 7,821 7,669 1.9 2,249 9.4
1996–1997 16,235 18,608 14.6 7,877 7,628 3.2 2,124 8.8
1997–1998 16,646 18,291 9.9 7,958 7,686 3.4 1,373 5.6
Extension phase
1998–1999 19,506 20,746 6.4 5,404 5,392 0.2 1,228 4.9
1999–2000 19,779 22,368 13.1 5,488 5,433 1.0 2,534 10.0
2000–2001 20,043 22,108 10.3 5,675 5,517 2.8 1,907 7.4
2001–2002 20,375 21,892 7.4 5,841 5,560 4.8 1,236 4.7
Steady-state phase
2002–2003 20,371 21,961 7.8 5,892 5,538 6.0 1,236 4.7
2003–2004 20,601 22,336 8.4 5,965 5,533 7.2 1,303 4.9
2004–2005 20,471 22,127 8.1 5,908 5,377 9.0 1,125 4.3
2005–2006 20,984 22,741 8.4 5,857 5,288 9.7 1,188 4.4
2006–2007 21,087 22,569 7.0 6,136 5,421 11.7 767 2.8
a The percentage of excess (E) breast cancers in the age group 0–69/74 years was calculated as (T1, age 0–69/74 years   T0, age 0–69/74 years)/
T0, age 0–69/74 years. T1, modeled number of breast cancers in the presence of screening; T0, predicted number of breast cancers in the absence
of screening. The percentage of deﬁcit (D) breast cancers was calculated as (T0, age 69/74–100 years   T1, age 69/74–100 years)/T0, age 69/74–100 years.
Overdiagnosis was then calculated as the number of excesscancers in the age group 0–69/74 years minus the number of deﬁcit cancers in the age
group 69/74–100 years divided by the total number of breast cancers in the absence of screening in women aged 0–100 years.
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(7, 19, 20, 23). In this case, the overdiagnosis estimate
would be 1.3 times higher than when women of all ages
are included (Table 3, estimator 2, 2006). Calculated as
the fraction of all breast cancers diagnosed in women of
the screening age in a situation with screening, comparable
to the estimates by Duffy et al. (6, 25) and Olsen et al. (24),
the estimate in the Netherlands would be 4.6% (Table 3,
estimator 4, 2006). If overdiagnosis is calculated as a frac-
tion of screen-detected cancers, the estimate would increase
by a factor of 3.2 (Table 3, estimator 5, 2006).
A comparable ﬁnding was shown by Welch and Black
(26), who demonstrated that the overdiagnosis rate in the
Malmo ¨ trial, previously estimated to be 10% (7), would be
24% if only screen-detected cancers were taken into ac-
count. The choice of the denominator will likely depend
on the purpose of the overdiagnosis estimate. If the popula-
tion risks of different screening regimens—for instance,
with varying starting ages for screening—are compared,
the denominator that includes all diagnosed breast cancers
in women aged 0–100 years may be useful. If the main
purpose is to inform individual women of their risk of being
overdiagnosed, the denominator that includes women of the
screening age and older may be more useful. The fraction of
screen-detected cancers overdiagnosed may be relevant in
evaluating the performance of a particular screening pro-
gram or in treatment decisions for DCIS.
Varying overdiagnosis estimates could also be explained
by differences in screening characteristics. For instance, the
more women are screened, the more likely that an irrelevant
tumor is detected. Thus, shorter screening intervals and
higher attendance rates may increase the overdiagnosis rate.
Overdiagnosis could also be affected by referral or recall
practice. If the threshold for diagnostic assessment of small
or obscure lesions is higher, fewer of these tumors may be
detected or overdiagnosed. The fraction of tumors that are
noninvasive may also inﬂuence overdiagnosis. In the United
States, for instance, 17%–34% of all screen-detected can-
cers are DCIS (31), whereas, in the Netherlands, this frac-
tion is somewhat lower (16%) (14).
Overdiagnosis estimates will also be affected by the age
of the screened group. In the Malmo ¨ trial, for instance, the
study group was 45–69 years of age at randomization. At 15
years of follow-up, they will be 60–84 years of age. Because
Table 3. Overdiagnosis Estimates in the Netherlands Using Various Estimators
a
Phase and Years
Estimator
1: (E 2 D)/
T0, age 0–100 years,
%
2: (E 2 D)/
T0, age 49–100 years,
%
3: (E 2 D)/
T0, age 49–69/74 years,
%
4: (E 2 D)/
T1, age 49–69/74 years,
%
5: (E 2 D)/SD,
%
6: T1, 49–69/74 years/
T0, 49–69/74 years,
%
Implementation phase
1990–1991 1.0 1.4 2.4 2.3 35.4 2.3
1991–1992 6.1 8.2 14.1 12.4 67.4 14.3
1992–1993 9.1 12.2 21.3 17.5 61.5 21.6
1993–1994 11.4 15.2 26.7 21.0 54.7 27.3
1994–1995 10.0 13.3 23.2 18.7 44.5 24.0
1995–1996 9.4 12.4 21.8 17.7 38.2 23.3
1996–1997 8.8 11.6 20.3 16.5 32.6 22.7
1997–1998 5.6 7.3 12.7 11.0 22.1 15.2
Extension phase
1998–1999 4.9 6.5 9.0 8.3 18.9 9.1
1999–2000 10.0 13.1 18.2 15.4 30.4 18.6
2000–2001 7.4 9.7 13.6 11.8 23.0 14.7
2001–2002 4.7 6.1 8.7 7.8 15.4 10.6
Steady-state phase
2002–2003 4.7 6.1 8.6 7.7 15.2 11.1
2003–2004 4.9 6.3 8.9 8.0 15.6 11.9
2004–2005 4.3 5.5 7.7 6.9 13.2 11.4
2005–2006 4.4 5.7 7.9 7.0 13.6 11.6
2006–2007 2.8 3.6 5.0 4.6 8.9 9.7
Abbreviation: SD, number of screen-detected cancers.
a E   D is the number of excess breast cancers (E) minus the number of deﬁcit breast cancers (D). The excess is calculated as the difference
between the modeled number of breast cancers with (T1) and the predicted number of breast cancers without (T0) screening in the screened age
group; the deﬁcit is calculated as the difference in the predicted number of breast cancers without and the modeled number of cancers with
screening in the age groups past the screening age.
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from causes other than breast cancer increases with age,
such trial-based estimates will be higher than overdiagnosis
estimates based on ongoing screening programs that have
a constant inﬂow of women in the lower age limit of screen-
ing. Another factor that might bias the overdiagnosis rate is
screening of women in the age groups no longer eligible for
screening (5, 9) or screening in the control group of a trial
(7). For instance, an estimated 24% of women in the control
group of the Malmo ¨ trial were thought to be screened (19).
Use of mathematical modeling to calculate overdiagnosis
has certain limitations. Overdiagnosis estimates will be af-
fected by model assumptions about the natural history of
breast cancer. Previous studies showed that model parame-
ters, such as test sensitivity, mean duration of the preclinical
phase of cancer, and probability of preclinical DCIS to pro-
gress to invasive cancer or to regress, can be interchanged to
some extent (32) (R. de Gelder, Erasmus MC, Department
of Public Health, unpublished manuscript). This means that,
for instance, a model with a higher progression and lower
regression rate of preclinical DCIS could simulate observed
breast cancer incidence equally well as a model with a lower
progression and higher regression rate, provided that test
sensitivity, mean duration, and onset rate of breast cancer
are adjusted accordingly. This might affect the overdiagno-
sis rate.
In the present study, the probability of DCIS progression
at age 50 years was estimated to be 61% and the probability
of regression to be 11%. If we instead assumed that 0% of
preclinical DCIS would progress and 96% would regress,
the predicted overdiagnosis rate would be 8.1% of all pre-
dicted cancers in 2006 (data not shown). This rate is still
considerably lower than the overdiagnosis estimates pub-
lished elsewhere (5, 9, 27). Because the natural history of
DCIS is unobservable, no direct evidence exists on the
‘‘true’’ progression and regression rate.
However, indirect evidence suggests that the assumed
progression rate in our model is plausible. For instance,
follow-up of undertreated DCIS initially misdiagnosed as
benign shows that 11%–60% of all DCIS recurs as invasive
cancer within 10–20 years (32). Furthermore, basement
membrane invasion has been observed in DCIS cases, and
microscopy on invasive lesions showed that DCIS was pres-
ent in 20%–30% of the carcinomas (33). Literature provides
no evidence on the fraction of preclinical DCIS that re-
gresses. Because of structural model uncertainties, it would
be useful to assess the overdiagnosis rate in one particular
screening situation with various collaborating models, such
as those in the Cancer Intervention and Surveillance Mod-
eling Network (CISNET) (34). These models share the same
input but vary in their structure and assumptions, which
reﬂects the uncertainties about the natural history of breast
cancer. Only some of the CISNET models incorporated
DCIS or assigned low malignant potential to a fraction of
the tumors (34), which would of course affect overdiagnosis
estimates.
The present study is limited by the fact that from 2002
onward, the modeled breast cancer incidence is lower than
the observed incidence among women of the screening ages
(Figure 2). However, increasing the sensitivity of mammog-
raphy in the model did not result in a substantial increase in
the modeled incidence, without affecting the predicted num-
ber of interval cancers or clinically diagnosed cancers (14).
The difference between observed and modeled incidence
rates should therefore be explained by an increasing trend
in background incidence. This could happen when breast
cancer incidence increases because of, for instance, a rising
prevalence of risk factors such as lower parity, older age at
birth of the ﬁrst child, or obesity. Increasing incidence
trends have been observed before implementation of the
Dutch screening program and in unscreened women (35,
36). Future modeling efforts should take such background
trends into account. Because increases in background in-
cidence are likely to occur in both screened and unscreened
w o m e na ta na p p r o x i m a t e l ys i m i l a rr a t e ,i ti su n l i k e l yt h a t
our overdiagnosis estimate, which did not include the sec-
ular increase in incidence, was affected by poor model ﬁt
in recent years. If we conservatively assume that improve-
ment in the sensitivity of mammography would have in-
creased the excess incidence by 10%, the overdiagnosis
estimate at steady-state screening would be 3.4%–5.6%.
Although the modeled incidence was lower than the actual
observed incidence in recent years, we modeled the ob-
served incidence between 1990 and 2002 fairly well. More-
over, the model reproduced the observed incidence decline
in women who are no longer screened accurately for all
observation years.
Despite several limitations, our approach to calculating
overdiagnosis has certain advantages. By using a model,
screened and nonscreened populations could be exactly
the same, with a similar background risk of developing
breast cancer. Studies that, for instance, compare screened
and historical comparison groups have the disadvantage that
temporal incidence trends may have affected one group
but not the other (e.g., by the use of hormone replacement
therapy in the late 1990s). Moreover, our approach has
the advantage that it is based on observed data from a
long-running, population-based mammography screening
program with high participation rates (82% in the target
population, 95% of previous attendees) that annually targets
more than a million women. The observed data on which
the model was based include clinically diagnosed breast
cancers, screen-detection rates, and interval cancer rates.
Natural history parameters, such as lead time, could be es-
timated from these data. The observations show that the
incidence of breast cancer strongly decreases after women
have reached the upper age limit for screening. This ﬁnding
strongly suggests that the risk of overdiagnosis must be
smaller than recent estimates of approximately 50% (5, 8,
9, 27).
In conclusion, our estimates of overdiagnosis are substan-
tially lower than those published in recent literature. This
discrepancy is most likely related to methodological differ-
ences between studies and lack of sufﬁcient follow-up, and
partly to differences in screening characteristics and perfor-
mance. In 2006, the estimated risk of overdiagnosis in the
Netherlands ranged between 2.8% of all predicted cancers
in women aged 0–100 years in the absence of screening
and 9.7% of all predicted cancers in women of the screening
age only.
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